Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population
Open Access
- 12 May 2020
- Vol. 10 (5), e032579
- https://doi.org/10.1136/bmjopen-2019-032579
Abstract
Background and objective Simulation models can project effects of tobacco use and cessation and inform tobacco control policies. Most existing tobacco models do not explicitly include relapse, a key component of the natural history of tobacco use. Our objective was to develop, calibrate and validate a novel individual-level microsimulation model that would explicitly include smoking relapse and project cigarette smoking behaviours and associated mortality risks. Methods We developed the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model, in which individuals transition monthly between tobacco use states (current/former/never) depending on rates of initiation, cessation and relapse. Simulated individuals face tobacco use-stratified mortality risks. For US women and men, we conducted cross-validation with a Cancer Intervention and Surveillance Modeling Network (CISNET) model. We then incorporated smoking relapse and calibrated cessation rates to reflect the difference between a transient quit attempt and sustained abstinence. We performed external validation with the National Health Interview Survey (NHIS) and the linked National Death Index. Comparisons were based on root-mean-square error (RMSE). Results In cross-validation, STOP-generated projections of current/former/never smoking prevalence fit CISNET-projected data well (coefficient of variation (CV)-RMSE≤15%). After incorporating smoking relapse, multiplying the CISNET-reported cessation rates for women/men by 7.75/7.25, to reflect the ratio of quit attempts to sustained abstinence, resulted in the best approximation to CISNET-reported smoking prevalence (CV-RMSE 2%/3%). In external validation using these new multipliers, STOP-generated cumulative mortality curves for 20-year-old current smokers and never smokers each had CV-RMSE ≤1% compared with NHIS. In simulating those surveyed by NHIS in 1997, the STOP-projected prevalence of current/former/never smokers annually (1998–2009) was similar to that reported by NHIS (CV-RMSE 12%). Conclusions The STOP model, with relapse included, performed well when validated to US smoking prevalence and mortality. STOP provides a flexible framework for policy-relevant analysis of tobacco and nicotine product use.Funding Information
- Massachusetts General Hospital (Steve and Deborah Gorlin MGH Research Scholars Awa)
- National Institute on Drug Abuse (K01 DA042687)
- National Heart, Lung, and Blood Institute (K01 HL123349)
This publication has 56 references indexed in Scilit:
- Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes MellitusDiabetes Technology & Therapeutics, 2019
- Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United StatesJAMA Internal Medicine, 2017
- Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling StudyThe Journal of Infectious Diseases, 2016
- Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokersBMJ Open, 2016
- A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine productsAddiction, 2016
- Modeling the Health Effects of Expanding e-Cigarette Sales in the United States and United Kingdom: A Monte Carlo Analysis.JAMA Internal Medicine, 2015
- Modeling the Potential Effects of New Tobacco Products and Policies: A Dynamic Population Model for Multiple Product Use and HarmPLOS ONE, 2015
- Predictors of smoking relapse by duration of abstinence: findings from the International Tobacco Control (ITC) Four Country SurveyAddiction, 2009
- Effect of Maintenance Therapy With Varenicline on Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Expanded Screening for HIV in the United States — An Analysis of Cost-EffectivenessThe New England Journal of Medicine, 2005